COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,870 Articles (22,568 medRxiv, 8,302 bioRxiv)

Most recent first Previous |  Page 2513: Articles 25121-25130  | Next

Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication
Garcia, G., Sharma, A., Ramaiah, A., Sen, C., Kohn, D., Gomperts, B., Svendsen, C. N., Damoiseaux, R. D., Arumugaswami, V.
10.1101/2020.06.24.150326 — Posted: 2020-06-25 Discussion: Onsite | Offsite
Chasing the origin of SARS-CoV-2 in Canada's COVID-19 cases: A genomics study
Sjaarda, C. P., Rustom, N., Huang, D., Perez-Patrigeon, S., Hudson, M. L., Wong, H., Guan, T. H., Ayub, M., Soares, C. N., Colautti, R. I., Evans, G. A., Sheth, P. M.
10.1101/2020.06.25.171744 — Posted: 2020-06-25
Molecular features similarities between SARS-CoV-2, SARS, MERS and key human genes could favour the viral infections and trigger collateral effects
Maldonado, L., Kamenetzky, L.
10.1101/2020.06.23.167072 — Posted: 2020-06-25
Cellular exocytosis gene (EXOC6/6B): a potential molecular link for the susceptibility and mortality of COVID-19 in diabetic patients
Taneera, J., Hachim, M. Y., Hachim, I. Y., Al Heialy, S., Sulaiman, N.
10.1101/2020.06.25.170936 — Posted: 2020-06-25 Discussion: Onsite
Increased Expression of Chondroitin Sulfotransferases following AngII may Contribute to Pathophysiology Underlying Covid-19 Respiratory Failure: Impact may be Exacerbated by Decline in Arylsulfatase B Activity
Bhattacharyya, S., Kotlo, K., Tobacman, J. K.
10.1101/2020.06.25.171975 — Posted: 2020-06-25
Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2
Nilles, E. J., Karlson, E. W., Norman, M., Gilboa, T., Fischinger, S., Atyeo, C., Zhou, G., Bennett, C. L., Tolan, N. V., Oganezova, K., Walt, D. R., Alter, G., Simmons, D. P., Schur, P., Jarolim, P., Baden, L. R.
10.1101/2020.06.24.20139006 — Posted: 2020-06-25
Surveillance testing of SARS-CoV-2
Larremore, D. B., Wilder, B., Lester, E., Shehata, S., Burke, J. M., Hay, J. A., Tambe, M., Mina, M. J., Parker, R.
10.1101/2020.06.22.20136309 — Posted: 2020-06-25 Discussion: Onsite | Offsite
An analysis of COVID-19 article dissemination by Twitter compared to citation rates
Fabiano, N., Hallgrimson, Z., Kazi, S., Salameh, J.-P., Wong, S., Kazi, A., Unni, R. R., Prager, R., McInnes, M. D.
10.1101/2020.06.22.20137505 — Posted: 2020-06-25
IMPACT OF COVID-19 PANDEMIC ON MENTAL HEALTH OF MEDICAL STUDENTS:A CROSS-SECTIONAL STUDY USING GAD-7 AND PHQ-9 QUESTIONNAIRES
Sartorao Filho, C. I., Rodrigues, W. C. d. L. V., Beauchamp de Castro, R., Marcal, A. A., Pavelqueires, S., Takano, L., Oliveira, W. L. d., Sartorao Neto, C. I.
10.1101/2020.06.24.20138925 — Posted: 2020-06-25
Liberte, Egalite, Fraternite... Contamine? Estimating the impact of French municipal elections on COVID-19 spread in France
Cassan, G., Sangnier, M.
10.1101/2020.06.24.20138990 — Posted: 2020-06-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).